Table 1.
55 characteristics
| N (%) | |
|---|---|
| Total | 26 (100) |
| Age | |
| median years | 67.6 |
| > 65 years | 16 (61.5) |
| Gender | |
| Male | 17 (65.4) |
| Female | 9 (34.6) |
| T-stage | |
| 1 | 1 (3.8) |
| 2 | 5 (19.2) |
| 3 | 8 (30.8) |
| 4 | 12 (46.2) |
| N-stage | |
| 0 | 5 (19.2) |
| 1 | 1 (3.8) |
| 2 | 14 (53.8) |
| 3 | 6 (23.1) |
| M 1 | 1 (3.8) |
| UICC 8th edition | |
| IIIA | 9 (34.6) |
| IIIB | 13 (50.0) |
| IIIC | 3 (11.5) |
| IVA | 1 (3.8) |
| PTV-size | |
| median cc | 680.3 |
| ≥ 700 cc | 12 (46.2) |
| Histology | |
| Squamous cell carcinoma (SCC) | 10 (38.5) |
| Adenocarcinoma (AC) | 12 (46.2) |
| Not otherwise specified (NOS) | 4 (15.4) |
| Radiographic imaging | |
| PET-CT | 25 (96.2) |
| cMRI | 23 (88.5) |
| Treatment | |
| Concurrent chemoradiation (CRT) | 25 (96.2) |
| Induction chemotherapy | 14 (53.8) |
| Median-FU months after CRT | 20.6 |
| OS | |
| 6-months | 100% |
| 12-months | 100% |
| PFS | |
| 6-months | 82% |
| 12-months | 62% |